LLL12B|CAS 2305051-60-7|DC Chemicals

Cas No.:	2305051-60-7
Chemical Name:	LLL12B
Formula:	C₁₇H₁₄N₂O₆S
M.Wt:	374.367

Cat. No.	Product name	Field of application
DC73586	STAT3-SH2 domain inhibitor 1	STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a Kd value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer.
DC70809	STAT3 inhibitor N4	STAT3 inhibitor N4 is a small molecule capable of inhibiting the STAT3 SH2 domain with IC50 of 0.57 uM, SPR KD of 1.04 uM, inhibits STAT3 dimerization and transcription in vitro and suppresses pancreatic cancer in vivo.N4 suppresses STAT3 activation in pancreatic cancer cells, suppresses pancreatic cancer cell growth, migration, and induces apoptosis.N4 (20 mg/kg, i.p.) suppresses pancreatic cancer growth, exhibits potent anti-metastatic activity in a pancreatic cancer liver metastasis mouse model, and prolongs survival of tumor-bearing mice.
DC45278	Colivelin	Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury
DC8726	FLLL31	FLLK31 is a potent and selective inhibitor of the STAT3 signaling pathway.
DC81832	STAT3-IN-13	STAT3-IN-13 (compound 6f) is a STAT3 inhibitor. It exhibits anti-proliferative activity and binds to the STAT3 SH2 domain with a KD of 0.46 μM. This compound inhibits STAT3 Y705 phosphorylation and downstream target gene expression. In vitro studies show STAT3-IN-13 induces apoptosis, while in vivo experiments demonstrate its ability to suppress tumor growth and metastasis. STAT3-IN-13 has potential applications in cancer research.
DC81831	STAT3-IN-12	STAT3-IN-12 is a potent inhibitor of STAT3signaling, by effectively blocking IL-6-induced activation of the JAK/STAT3 pathway. STAT3-IN-12 suppresses cancer cell proliferation and migration, while promoting apoptosis and inducing cell cycle arrest.
DC81528	SGK1-IN-9	SGK1-IN-9 (Compound 1) is a SGK1 inhibitor. SGK1-IN-9 can be used in cancer research.
DC80739	GRM1 modulator-1	GRM1 modulator-1 is a GRM1 modulator.
DC80533	DHX9-IN-21	DHX9-IN-21 (Compound 635) is a DHX9 inhibitor with an IC50 of 2 nM; its EC50 at the cellular level is 19.1 nM. DHX9-IN-21 exhibits antiproliferative activity against LS411N (CRC-MSI-H), with an IC50 value of 79.2 nM. DHX9-IN-21 can be used for the research of microsatellite unstable colorectal cancer.
DC80491	CTR/AMYR modulator-1	CTR/AMYR modulator-1 is a calcitonin receptor/amylin receptor modulator. CTR/AMYR modulator-1 can be used for the research of metabolic disease.